Trial Profile

To Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Relapsed and Refractory Acute B-cell Leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ThisCART 19 (Primary) ; Cyclophosphamide; Etoposide; Fludarabine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

17 Feb 2026 Number of treatment arms are decreased from 3 to 2 by the removal of Experimental: ThisCART19A 12x10^6 cells/kg as dose level 3 arm. Doses in the existing 2 arms are also reduced.
17 Feb 2026 Actual Primary Completion Date is 21 May 2025.
17 Feb 2026 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com